By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


CSL Behring 

1020 First Avenue
P.O. Box 61501
King of Prussia  Pennsylvania  19406-0901  U.S.A.
Phone: 610-878-4000 Fax: 610-878-4009



Company News
CSL Behring Awards Young Researchers Around The World To Advance Coagulation Science 4/24/2015 12:25:25 PM
CSL Behring Marks World Hemophilia Day By Renewing Pledge To World Federation Of Hemophilia 4/14/2015 11:12:54 AM
European Medicines Agency Commences Review Of CSL Behring's Regulatory Submission For Rix-FP For Hemophilia B Patients 3/30/2015 12:50:45 PM
The Lancet Publishes CSL Behring's Kcentra Phase III Data 3/17/2015 7:25:40 AM
CSL Behring To Provide $80,000 In Scholarship Funding For Low-Income Students In Philadelphia Area 3/9/2015 10:36:44 AM
CSL Behring Continues Treatment Access Leadership By Donating Bleeding Disorder Protein Therapies IUs To World Federation Of Hemophilia 2/27/2015 10:31:03 AM
U.S. FDA Accepts For Review CSL Behring's Biologics License Application For rIX-FP For Hemophilia B Patients 2/4/2015 11:11:40 AM
Snag a Job: Here's How CSL Behring Makes Hiring Decisions 2/3/2015 4:51:41 PM
FDA Approves New Dosing Option for CSL Behring's Hizentra® 2/2/2015 9:20:36 AM
CSL Behring Submits Biologics License Application For FDA Approval Of Recombinant Fusion Protein Linking Coagulation Factor IX With Recombinant Albumin (Rix-FP) For Hemophilia B Patients 12/16/2014 8:36:38 AM